• RebeccaDr. Rebecca, MBBS. Department of Ophthalmology, Isra University Hospital, Hyderabad, Pakistan., Fahad Feroz Shaikh, and Shafi Muhammad Jatoi.
• Dr. Rebecca, MBBS. Department of Ophthalmology, Isra University Hospital, Hyderabad, Pakistan.
• Pak J Med Sci. 2021 Jan 1; 37 (1): 157-161.

ObjectiveTo compare efficacy of intravitreal bevacizumab augmented with Panretinal photocoagulation versus Panretinal photocoagulation alone in high risk proliferative diabetic retinopathy.MethodsThis is Randomized clinical control trial study conducted at ISRA University Hospital, Hyderabad from July 2018 to December 2018. A total of 76 eyes were randomized into two groups, 38 eyes undergone PRP plus intravitreal bevacizumab, while 38 eyes had PRP alone. Status of neovessels was assessed before and after treatment with the help of fundus fluorescein angiography. Neovessels at disc (NVD's) and neovessels elsewhere (NVE's) were assessed with the disc surface diameter.ResultsSeventy-six eyes were enrolled in this randomized clinical trial into two groups consecutively, that all completed the six months follow-up. In the PRP group mean BCVA (logMAR) worsened significantly from mean 0.30±0.07 to mean 0.40±0.04 at a 30th day and mean 0.40±0.04 at day 90. While BCVA become improved from 0.30±0.05 to 0.1±0.03 at week four and 0.1±0.02 at week 12 in PRP-Plus group. There was significant change in regression of NVES in PRP only group at week 4 is 2.25±0.75 (p=0.00004) and at 12 weeks 2.00±0.50 (p=0.00002), while in PRP + intravitreal bevacizumab group at 4th week was 1±0.5 (p =0.0001) and at 12th week was 0.75±0.25 (p=0.0001).ConclusionIntravitreal Bevacizumab augmented with PRP is more effective in early regression of neovessels in high risk PDR patients.Copyright: © Pakistan Journal of Medical Sciences.

4 keywords...

hide…